Advances in hepatitis C therapy: What is the current state - what come's next?

World Journal of Hepatology
Steffen ZopfJuergen Siebler

Abstract

Chronic hepatitis C virus (HCV) infection affects 80-160 million people worldwide and is one of the leading causes of chronic liver disease. It is only a few years ago that standard treatment regimes were based on pegylated interferon alpha and ribavirin. However, treatment of HCV has undergone a revolutionary change in recent years. The admission of the nucleotide polymerase inhibitor Sofosbuvir enabled an interferon-free regimen with direct antiviral agents (DAA). Meanwhile seven DAAs are available and can be applied in several combinations for 8 to 24 wk depending on HCV genotype and patient characteristics such as cirrhosis and chronic renal failure. High rates of sustained virological response (SVR) rates can be achieved with these novel drugs. Even in difficult to treat populations such as patients with liver cirrhosis, HCV-human immunodeficiency virus co-infections, after liver transplantion, or with chronic kidney disease comparable high rates of SVR can be achieved. The anticipated 2(nd) generation DAAs are strikingly effective in patients so far classified as difficult to treat including decompensated liver cirrhosis or post-transplant patients. These 2(nd) generations DAAs will have higher resistance barriers, higher...Continue Reading

References

Dec 18, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Nabil AntakiPatrick Marcellin
Nov 26, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D Lavanchy
Mar 5, 2011·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 1, 2011·The New England Journal of Medicine·Bruce R BaconUNKNOWN HCV RESPOND-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Jan 4, 2013·The New England Journal of Medicine·Edward J GaneM Michelle Berrey
Apr 24, 2013·The New England Journal of Medicine·Ira M JacobsonUNKNOWN FUSION Study
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
Apr 12, 2014·The New England Journal of Medicine·Stefan ZeuzemBarry Bernstein
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Apr 12, 2014·The New England Journal of Medicine·Jordan J FeldBarry Bernstein
Apr 15, 2014·The New England Journal of Medicine·Fred PoordadBarry Bernstein
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
Apr 18, 2014·The New England Journal of Medicine·Mark S SulkowskiDavid R Nelson
Apr 18, 2014·The New England Journal of Medicine·Harpal S Dhaliwal, Ram V Nampoothiri
May 2, 2014·Seminars in Liver Disease·Daniel Rupp, Ralf Bartenschlager
May 6, 2014·The New England Journal of Medicine·Peter FerenciUNKNOWN PEARL-IV Study
May 6, 2014·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN VALENCE Investigators
Nov 12, 2014·The New England Journal of Medicine·Paul Y KwoXavier Forns
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David R NelsonUNKNOWN ALLY-3 Study Team
Feb 24, 2015·JAMA : the Journal of the American Medical Association·Anu OsinusiShyam Kottilil
May 6, 2015·JAMA : the Journal of the American Medical Association·Fred PoordadUNKNOWN UNITY-1 Study Group
May 6, 2015·JAMA : the Journal of the American Medical Association·Andrew J MuirPhilip D Yin
May 20, 2015·Gastroenterology·Michael CharltonUNKNOWN SOLAR-1 Investigators
Jun 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·UNKNOWN AASLD/IDSA HCV Guidance Panel

❮ Previous
Next ❯

Citations

Jul 13, 2016·International Journal of Hepatology·Allison M BellKayla R Stover
Jul 23, 2016·Frontiers in Pharmacology·Giada SebastianiKostas Pantopoulos
Aug 24, 2016·Journal of Medical Virology·Sebastián MarcianoAdrián Gadano
Oct 16, 2016·International Journal of Molecular Sciences·Claudia MinosseAnna R Garbuglia
Nov 12, 2016·Lancet·Veronika J WirtzMichael R Reich
Aug 11, 2016·Journal of Medical Virology·C Nelson Hayes, Kazuaki Chayama
Oct 4, 2016·Experimental Biology and Medicine·Charles B NguyenNaushad Ali
Mar 21, 2018·Antimicrobial Agents and Chemotherapy·Nagraj ManiMichael J Sofia
Aug 8, 2018·The Indian Journal of Medical Research·Anoop KumarSurinder Singh
Dec 27, 2019·The Health Care Manager·Maggie PhillipsAlberto Coustasse
Aug 2, 2016·World Journal of Hepatology·Sylvie LagayeStanislas Pol
Mar 18, 2017·Scientific Reports·Matteo CastelliNicasio Mancini
Aug 10, 2016·Antiviral Chemistry & Chemotherapy·Wataru ItoMasanori Baba
Jan 11, 2017·The Journal of Antimicrobial Chemotherapy·Hong-Tao XuMark A Wainberg
Sep 22, 2017·World Journal of Hepatology·Reza Taherkhani, Fatemeh Farshadpour
Jul 20, 2016·World Journal of Hepatology·Aldo Bonaventura, Fabrizio Montecucco
Dec 23, 2017·Expert Opinion on Investigational Drugs·Guglielmo BorgiaAntonio Riccardo Buonomo
Aug 12, 2017·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Alice SannaChristine Larsen
Jul 20, 2016·World Journal of Gastroenterology : WJG·Babita Agrawal, Rakesh Kumar
Aug 2, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Tarik AsselahAlessandra Mangia
Aug 18, 2018·Experimental and Therapeutic Medicine·Tomoko TadokoroTsutomu Masaki
Oct 1, 2016·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Steffen ZopfDeike Strobel
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CouronnéO Hermine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation
Amna Subhan ButtWasim Jafri
Expert Opinion on Emerging Drugs
Aybike Birerdinc, Zobair M Younossi
Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology
Evangelos Cholongitas, George V Papatheodoridis
Liver International : Official Journal of the International Association for the Study of the Liver
Tarik Asselah, Patrick Marcellin
© 2021 Meta ULC. All rights reserved